Brind.
  1. IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services.

IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

IDEXX customers are shifting pancreatic lipase testing to the Catalyst instrument platform.

Who's involved

What this event is mainly about
IDEXX Laboratories, Inc.catalyst

How it developed

Newest first. Tap a step to see who reported it.
  1. Higher revenue drove increased profit margin for IDEXX Laboratories, Inc. on August 5, 2025.Sub-event
  2. IDEXX customers are adopting the Catalyst platform for pancreatic lipase testing.1 source

Keep exploring

Part of

IDEXX Laboratories' CEO, Mike Erickson, commented on the company's scaling strategy and announced the rollout of new diagnostic services. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GuruFocus.comIDEXX Laboratories Inc (IDXX) Q2 2025 Earnings Call Highlights: Strong Revenue and EPS Growth ... Revenue Growth: Increased 11% as reported and 9% organically. CAG Diagnostic Recurring Revenues: Grew